Status:
COMPLETED
Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate
Lead Sponsor:
Timothy Showalter, MD
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Radiation therapy is one of the standard treatments for men with prostate cancer who have detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker) after surgery. When ra...
Detailed Description
Primary Objectives: To determine the shortest dose-fractionation schedule (Dose Schedule) with acceptable grade ¡Ã 3 GU/GI toxicity rate for salvage HypoFx RT to maintain a constant, high BED for pro...
Eligibility Criteria
Inclusion
- diagnosis of prostate adenocarcinoma and
- have had a prostatectomy
- have detectable PSA
- 18 years of age or older
Exclusion
- are receiving chemotherapy or other agents intended for cancer treatment
- history of rectal surgery or lower gastrointestinal bleed
- history of bleeding diathesis or abnormal sensitivity to ionizing radiation
- had prior pelvic irradiation or are scheduled to receive pelvic nodal irradiation
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01868386
Start Date
April 1 2013
End Date
December 1 2020
Last Update
April 28 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
2
Southwest Virginia Regional Cancer Center
Norton, Virginia, United States, 24273
3
Virginia Commonwealth University
Richmond, Virginia, United States, 23220